Brief: Can Medicare Help More Patients Stay on Home Dialysis?

Key Takeaways

• Bill adds Medicare-paid respite care and mental‑health visits for home dialysis
• Waiver removes budget‑neutral requirement, allowing incremental reimbursement
• Support could cover up to 4.9% of annual ESRD base payments
• Early‑stage payments may represent 22‑30% of first two months’ costs
• Home dialysis share reached 15% of ESRD patients in 2023

Pulse Analysis

Home dialysis has long been touted as a patient‑centric alternative to in‑center treatment, yet its adoption has been hampered by steep learning curves, caregiver strain, and limited safety nets during the early transition period. Studies show technique failure rates ranging from 2% to 30% for home hemodialysis and 6% to 40% for peritoneal dialysis, with most attrition occurring within the first months. These gaps have prompted policymakers to look beyond modality education and equipment, focusing on the “messy middle” where patients need hands‑on assistance and mental‑health support to stay at home.

The Improving Home Dialysis Act seeks to fill that gap by authorizing Medicare to pay for staff‑assisted respite care and up to four renal mental‑health sessions during the first 30‑60 days of home therapy. Crucially, the bill includes a budget‑neutrality waiver, allowing the new payments to be added on top of the existing ESRD Prospective Payment System rather than reshuffled from other line items. At current rates, the support translates to roughly 3.6% of annual base‑rate payments for non‑rural patients and up to 4.9% for rural beneficiaries, but it could represent 22%‑30% of the cash flow in the critical early‑stage window. While the per‑session mental‑health reimbursement—about $24—appears modest, the policy signal may encourage providers to develop bundled staffing models that capture economies of scale.

For dialysis operators and home‑care firms, the act offers a clearer business case to invest in transitional staffing, remote monitoring, and interdisciplinary care teams. Value‑based contracts and Medicare Advantage arrangements already reward cost‑effective home dialysis, and the added reimbursement could accelerate adoption by reducing the financial risk of early failures. However, the bill’s success will hinge on CMS’s rulemaking—defining qualified personnel, billing mechanisms, and quality metrics. If implemented flexibly, the policy could serve as a catalyst for broader home‑support infrastructure, ultimately expanding access, lowering hospitalizations, and strengthening the overall kidney‑care ecosystem.